Screen Reader Mode Icon
Thank you for your ongoing support for our SME R&D tax relief campaign highlighting the negative impact of the relief rate changes announced in the Autumn Statement for biotech.
 
Thanks to our combined effort, the Chancellor has said he sees “merit to the case for further support” for “R&D intensive businesses”.

To help inform what the BIA calls for in the next stage of our campaign, we urgently need to know the R&D intensity of businesses in our sector, defined as expenditure on R&D as a percentage of total operating costs.

Please help us and the sector by completing this short survey by midnight on Wednesday 8 February. We will not share your company’s individual data with anyone outside BIA, but we may share the combined sector data with government officials.  

Please provide aggregate data from your most recent full financial year for all UK companies (including holding companies not undertaking R&D but excluding any overseas companies).
 

Question Title

* 1. Company name

Question Title

* 2. Brief description of company, e.g. oncology drug development company, genomics technology company, or medical screening company etc (max 50 words)

Question Title

* 3. UK headcount

Question Title

* 4. Total R&D tax relief eligible spend in most recent financial year (including sub-contract and EPW) for all UK companies in the group

Question Title

* 5. Of the above expenditure from Question 4, the total amount attributed to sub-contract and EPW spend (please provide the amount included in the claim net of the 35% restriction)

Question Title

* 6. Total annual expenditure excluding interest (but including R&D) for all group UK companies.

This is the total aggregate annual expenditure in the profit and loss account for all group UK companies (including holding companies)

This should include:
  • R&D expenditure
  • depreciation and amortisation
But exclude
  • expenditure capitalised in the period
  • Interest

Question Title

* 7. Your email address (optional). We would like to be able to contact you for further information should we need it.

0 of 7 answered
 

T